Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lasofoxifene

Small molecule · Modulator of estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2) · developed by Ligand Pharmaceuticals

Phase 3 Most advanced trial (none active)
LGND Developer
1 Registered trials

What is Lasofoxifene?

Lasofoxifene is a non-steroidal, third-generation selective estrogen receptor modulator that binds estrogen receptor alpha and beta with high affinity, acting as an agonist in some tissues and an antagonist in others.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
estrogen receptor alpha (ESR1), estrogen receptor beta (ESR2)
Mechanism
Modulator of estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2)
Pathways
estrogen receptor signaling
Therapy area
Metabolic, Musculoskeletal
Developer
Ligand Pharmaceuticals (LGND)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
337G83N988

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00141323 Phase 3 Osteoporosis Completed LGND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Osteoporosis

Other drugs acting on ESR1 / ESR2

More from Ligand Pharmaceuticals

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LGND page.

Follow LGND, the company behind Lasofoxifene

See LGND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LGND catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.